Indications of Margetuximab/Meganex

Margetuximab (Margetuximab) is an innovative anti-HER2 targeted therapy drug, mainly used to treat patients with metastatic HER2-positive breast cancer. HER2 (human epidermal growth factor receptor 2) is a receptor overexpressed on the surface of breast cancer cells and is involved in the proliferation and expansion of tumor cells. About 20%-25% of breast cancer patients are HER2 positive, which means their cancer cells express an excess of HER2 receptors, and this type of breast cancer usually grows rapidly and is prone to metastasis.

The indications for margetuximab are mainly focused on the treatment of patients with metastatic HER2-positive breast cancer who have received two or more anti-HER2 therapies. The drug is approved for use in combination with chemotherapy in patients who have failed or are resistant to previous treatments. Especially in these patients, margituximab offers a new treatment option by targeting the HER2 receptor, blocking the growth of cancer cells while enhancing the immune system's anti-tumor capabilities.

Specifically, the combination of margetuximab and chemotherapy can significantly improve the efficacy of patients with metastaticHER2-positive breast cancer. These patients have often been treated with anti-HER2 therapeutic drugs such as trastuzumab (Herceptin) and pertuzumab (Perjeta), and over time, many patients may develop resistance to these drugs. The mechanism of action of margetuximab can break through the resistance barrier and provide patients with new treatment opportunities.

One of the advantages of margetuximab as a targeted therapy is that it can exert a stronger anti-tumor effect by enhancing the immune response. This allows it to not only rely on the traditional mechanism of chemotherapy drugs, but also to enhance the therapeutic effect through the immune system.

In summary, the indications for margetuximab are mainly focused on the treatment of metastatic HER2-positive breast cancer, especially those patients who have received two or more anti-HER2 regimens and developed resistance.

Reference materials: https://www.margenza.com/